← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #80 OF 1,000 MOST-CITED

Lack of or inadequate procedures - Acceptance activities

FDA cited this observation 322 times across 297 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices322
BY FISCAL YEAR
FY20265
FY202536
FY202427
FY202327
FY202241
FY202116
FY202022
FY201941
FY201837
FY201740
FY201630

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.7× the rate of the average FDA-cited firm (12.8% vs 7.7%), across 297 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Procedures for acceptance activities have not been adequately established.

Avokaid, LLC · Plano, Texas · Devices · 2025-11-25

Procedures for acceptance activities have not been adequately established.

Pathright Medical Inc · Orem, Utah · Devices · 2025-11-17

Procedures for acceptance activities have not been established.

Splintek, Inc · Lenexa, Kansas · Devices · 2025-10-30

Procedures for acceptance activities have not been adequately established.

Flextronics America LLC · Austin, Texas · Devices · 2025-10-30

Procedures for acceptance activities have not been adequately established.

Homtex Inc · Cullman, Alabama · Devices · 2025-10-16

Procedures for acceptance activities have not been established.

Henke Sass Wolf Of America,Inc · Dudley, Massachusetts · Devices · 2025-09-16

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemMedical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →